•  
  •  
  •  
  •  

2025-06-21 07:50:49

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Amic Forging Limited enters into agreement for asset purchase
  • BuzzWorks Expands Hyderabad Footprint
  • GMM Pfaudler Limited arm enters into contract for EUR 33.2 Mn
  • TD Power Systems Limited receives order valued at approx. Rs. 67 crore
  • Diageo India to acquire NAO Spirits, maker of premium Indian craft gin brands like 'Greater Than' and 'Hapusa'

Keywords Selected:  Pharmaceuticals

Research

  • CRISIL: Pharmaceutical sector set for 8-10% revenue growth this fiscal
  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassador
  • Closure of USFDA inspection at Zydus' oncology injectable plant at Ahmedabad
  • Welcure Drugs & Pharmaceuticals Ltd secures ₹517 Crore Global Sourcing Mandate
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for API-III facility at Karakhadi
  • U.S. FDA inspection at Glenmark Pharma's Facility at Monroe, North Carolina, USA
  • Hikal Ltd successfully completes ANVISA GMP audit of Jigani unit
  • Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China
  • USFDA conducts GCP inspection at Syngene International Ltd's facility at Semicon Park, Bengaluru
  • Syngene International Ltd updates on USFDA inspection at Biocon Park, SEZ, Bengaluru
  • IOL Chemicals and Pharmaceuticals Ltd registers Acetic Anhydride with REACH
  • Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassado
  • Zydus receives EIR for the API manufacturing facility at Ankleshwar
  • IOL awarded EcoVadis Silver Medal - Ranks Among the Top 15% companies globally
  • Zydus receives EIR for the API manufacturing facility at Dabhasa
  • Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA® in India to Advance Treatment of Hematological Malignancies
  • Lupin receives tentative approval from U.S. FDA for Oxcarbazepine ER Tablets
  • CARBOGEN AMCIS AG., has entered into a co-investment agreement of more than CHF 25 million with a key client to expand Swiss sites
  • Gland Pharma Receives Approval for Angiotensin II Acetate Injection
  • Zydus enters global biologics CDMO business, plans to acquire Agenus’ U.S. manufacturing facilities to accelerate development of innovative therapies
  • Indoco Remedies Ltd announces the first day launch of Ticagrelor filmcoated tablets through its subsidiary in the United Kingdom
  • Piramal Pharma Ltd completes USFDA inspection of Aurora facility with Zero Form-483 observations
  • Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
  • Divi's Laboratories inks long term manufacturing and supply agreement with global pharma company
  • USFDA classifies Medgel Pvt Ltd's facility as VAI

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • Amic Forging Limited enters into agreement for asset purchase
  • BuzzWorks Expands Hyderabad Footprint
  • GMM Pfaudler Limited arm enters into contract for EUR 33.2 Mn
  • TD Power Systems Limited receives order valued at approx. Rs. 67 crore
  • Diageo India to acquire NAO Spirits, maker of premium Indian craft gin brands like 'Greater Than' and 'Hapusa'


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024